{"id":114356,"date":"2025-02-24T22:42:42","date_gmt":"2025-02-24T14:42:42","guid":{"rendered":"http:\/\/www.gocpmall.com\/?p=114356"},"modified":"2025-02-24T22:42:42","modified_gmt":"2025-02-24T14:42:42","slug":"2%e6%9c%8818%e6%97%a5%e8%82%a1%e5%b8%82%e5%bf%85%e8%af%bb%ef%bc%9a%e6%81%92%e7%91%9e%e5%8c%bb%e8%8d%af%ef%bc%88600276%ef%bc%89%e5%bd%93%e6%97%a5%e4%b8%bb%e5%8a%9b%e8%b5%84%e9%87%91%e5%87%80%e6%b5%81","status":"publish","type":"post","link":"https:\/\/www.gocpmall.com\/?p=114356","title":{"rendered":"2\u670818\u65e5\u80a1\u5e02\u5fc5\u8bfb\uff1a\u6052\u745e\u533b\u836f\uff08600276\uff09\u5f53\u65e5\u4e3b\u529b\u8d44\u91d1\u51c0\u6d41\u51651247.12\u4e07\u5143\uff0c\u5360\u603b\u6210\u4ea4\u989d0.79%_\u8d22\u5bcc\u53f7_\u4e1c\u65b9\u8d22\u5bcc\u7f51"},"content":{"rendered":"

\"news
截至2025年2月18日收盘，恒瑞医药(600276)报收于44.82元，下跌0.97%，换手率0.55%，成交量35.02万手，成交额15.82亿元。 当日关注点交易信息汇总：当日主力资金净流入1247.12万元，占总成交额0.79%。公司公告汇总：恒瑞医药子公司成都盛迪医药有限公司的HR19034滴眼液药品上市许可申请获得国家药品监督管理局受理，用于延缓6至12岁儿童近视进展。交易信息汇总 当日主力资金净流入1247.12万元，占总成交额0.79%；游资资金净流出1853.0万元，占总成交额1.17%；散户资金净流入605.88万元，占总成交额0.38%。 公司公告汇总恒瑞医药关于药品上市许可申请获受理的提示性公告： 近日，江苏恒瑞医药股份有限公司子公司成都盛迪医药有限公司收到国家药品监督管理局下发的《受理通知书》，公司HR19034滴眼液的药品上市许可申请获受理。药品名称为HR19034滴眼液，剂型为眼用制剂，受理号为CXHS2500019，拟定适应症为用于延缓等效球镜度数为-0.50D至-4.00D（散光≤1.50D、屈光参差≤1.50D）的6至12岁儿童近视进展。 2024年8月，HR19034滴眼液Ⅱ\/Ⅲ期临床试验（HR19034-301）达到了方案预设的主要研究终点。该研究是一项在儿童近视患者中评价HR19034滴眼液的有效性和安全性的随机、双盲和安慰剂对照Ⅱ\/Ⅲ期研究，共入组509例儿童近视患者。HR19034滴眼液在主要终点上显著优于对照组，且在儿童近视患者中长期治疗的安全性、耐受性良好。 当前全球近视患病率呈快速增长趋势，预计至2050年全球将有47.58亿近视人口，占总人口的49.8%。2020年中国儿童青少年近视患病率为52.7%。HR19034滴眼液是公司采用B\/F\/S三合一灌装技术开发的一种单剂量滴眼液，其活性成份为硫酸阿托品，无需添加防腐剂。截至目前，HR19034滴眼液相关项目累计已投入研发费用约5,032万元。 以上内容为证券之星据公开信息整理，由智能算法生成（网信算备310104345710301240019号），不构成投资建议。 本文作者可以追加内容哦 !
阅读更多（Read More）<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

截至2025年2月18日收 […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-114356","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/www.gocpmall.com\/index.php?rest_route=\/wp\/v2\/posts\/114356","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.gocpmall.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.gocpmall.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.gocpmall.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.gocpmall.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=114356"}],"version-history":[{"count":0,"href":"https:\/\/www.gocpmall.com\/index.php?rest_route=\/wp\/v2\/posts\/114356\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.gocpmall.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=114356"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.gocpmall.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=114356"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.gocpmall.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=114356"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}